In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads to loss of kidney function with limited therapeutic options. Here we describe results of Phase 1a escalating dose clinical trial of autologous mesenchymal stem cell infusion for ARVD. Thirty-nine patients with...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Kidney Int
Main Authors: Abumoawad, Abdelrhman, Saad, Ahmed, Ferguson, Christopher M., Eirin, Alfonso, Herrmann, Sandra M., Hickson, LaTonya J., Goksu, Busra B., Bendel, Emily, Misra, Sanjay, Glockner, James, Dietz, Allan B., Lerman, Lilach O., Textor, Stephen C.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7284953/
https://ncbi.nlm.nih.gov/pubmed/32093917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kint.2019.11.022
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki